articleAnnals of OncologyAug 9, 2022Closed access

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

SLSibylle LoiblASAndreas SchneeweißJHJens HuoberMBMichael BraunJRJulia Rey

German Cancer Research Center · National Center for Tumor Diseases · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

235
total citations
FWCI
19.75
Percentile
100%
References
27
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Medicine
  • Durvalumab
  • Hazard ratio
  • Breast cancer
  • Internal medicine
  • Oncology
  • Placebo
  • Epirubicin
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding